Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Frontiers in Bioscience : a Journal and Virtual Library|December 22, 2005
Stop Flow in abdominal and pelvic cancer relapsesRosario Vincenzo Iaffaioli, Gaetano Facchini, Anna Tortoriello, et al.
The Oncologist|September 2, 2017
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic ChemotherapyValentina Fanotto, Mario Uccello, Irene Pecora, et al.
Therapeutic Advances in Medical Oncology|August 28, 2020
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocolAntonio Avallone, Maria Carmela Piccirillo, Elena Di Gennaro, et al.
Tumori|June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-SMaria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
BMC Cancer|February 10, 2016
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)Antonio Avallone, Maria Carmela Piccirillo, Luigi Aloj, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia MeridionaleGiuseppe Colucci, Vittorio Gebbia, Giancarlo Paoletti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2025
Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM studyDavide Ciardiello, Luca Boscolo Bielo, Stefania Napolitano, et al.
The Oncologist|January 5, 2019
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study SubanalysisClaudio Vernieri, Fabio Galli, Laura Ferrari, et al.
Nature Medicine|March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancerJoris van de Haar, Xuhui Ma, Salo N Ooft, et al.
Pageof 9